Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1% Market Closed
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Green Cross Corp
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Selling, General & Administrative
-â‚©262.4B
CAGR 3-Years
2%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Celltrion Inc
KRX:068270
Selling, General & Administrative
-â‚©802.1B
CAGR 3-Years
-31%
CAGR 5-Years
-27%
CAGR 10-Years
-27%
SK Bioscience Co Ltd
KRX:302440
Selling, General & Administrative
-â‚©62.6B
CAGR 3-Years
-27%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Selling, General & Administrative
-â‚©104.2B
CAGR 3-Years
-20%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Selling, General & Administrative
-â‚©84.4B
CAGR 3-Years
-32%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Selling, General & Administrative
-â‚©13.2B
CAGR 3-Years
1%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Selling, General & Administrative?
Selling, General & Administrative
-262.4B KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Selling, General & Administrative amounts to -262.4B KRW.

What is Green Cross Corp's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-8%

Over the last year, the Selling, General & Administrative growth was 7%. The average annual Selling, General & Administrative growth rates for Green Cross Corp have been 2% over the past three years , -8% over the past five years , and -8% over the past ten years .

Back to Top